Sphingosine-1 Phosphate (S1P) Receptor Modulators: The Latest Evidence & Clinical Strategies for Ulcerative Colitis (UC)
Sphingosine-1 Phosphate (S1P) Receptor Modulators: The Latest Evidence & Clinical Strategies for Ulcerative Colitis (UC) is organized by Prime Education, LLC.
Release Date: November 17, 2023
Expiration Date: November 16, 2024
Description:
The therapeutic landscape for ulcerative colitis (UC) is rapidly expanding to include treatments with novel mechanisms of action. Among these are the sphingosine-1 phosphate (S1P) receptor modulators, a new class of small molecule therapies for patients with moderately to severely active disease.
In this video, hear leading experts discuss the latest clinical evidence and practical strategies for integrating S1P receptor modulators into practice and see how your knowledge compares with that of other clinicians in interactive questions and case-based scenarios.
Don't miss this dynamic discussion and opportunity to:
• Review advances in our understanding of UC pathophysiology and novel treatment targets illustrated through video animation
• Hear experts analyze the latest clinical evidence and discuss applications for new and emerging S1P receptor modulators for UC
• Assess your knowledge of the optimal use of novel therapies in clinical cases and see how your skills stack up with other providers
Learning Objectives:
• Differentiate the inflammatory pathways and mediators involved in the pathogenesis of ulcerative colitis (UC)
• Recognize the role of oral small molecule inhibitors in the evolving UC pharmacologic landscape
• Evaluate new and emerging targeted therapies for UC based on the latest clinical efficacy and safety data, as well as their mechanisms of action and routes of administration
• Develop guideline-informed and personalized UC management plans that integrate patient- and disease-specific factors into treatment decisions